nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP2E1—Dacarbazine—melanoma	0.102	0.155	CbGbCtD
Ondansetron—CYP1A2—Carmustine—melanoma	0.0971	0.148	CbGbCtD
Ondansetron—CYP1A2—Vemurafenib—melanoma	0.0768	0.117	CbGbCtD
Ondansetron—CYP3A4—Temozolomide—melanoma	0.0734	0.112	CbGbCtD
Ondansetron—CYP2D6—Vemurafenib—melanoma	0.0633	0.0966	CbGbCtD
Ondansetron—CYP1A2—Dacarbazine—melanoma	0.0589	0.0898	CbGbCtD
Ondansetron—CYP3A7—Docetaxel—melanoma	0.0472	0.072	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0472	0.072	CbGbCtD
Ondansetron—CYP3A4—Vemurafenib—melanoma	0.0402	0.0614	CbGbCtD
Ondansetron—CYP3A5—Docetaxel—melanoma	0.0354	0.054	CbGbCtD
Ondansetron—CYP3A4—Docetaxel—melanoma	0.0138	0.0211	CbGbCtD
Ondansetron—Electrocardiogram QT prolonged—Vemurafenib—melanoma	0.00428	0.0202	CcSEcCtD
Ondansetron—Raised liver function tests—Dactinomycin—melanoma	0.00336	0.0159	CcSEcCtD
Ondansetron—Neoplasm malignant—Vemurafenib—melanoma	0.00322	0.0152	CcSEcCtD
Ondansetron—Grand mal convulsion—Carmustine—melanoma	0.00305	0.0144	CcSEcCtD
Ondansetron—Local reaction—Bleomycin—melanoma	0.00301	0.0142	CcSEcCtD
Ondansetron—Musculoskeletal pain—Vemurafenib—melanoma	0.00278	0.0131	CcSEcCtD
Ondansetron—Atrial fibrillation—Vemurafenib—melanoma	0.0021	0.00993	CcSEcCtD
Ondansetron—Raised liver function tests—Docetaxel—melanoma	0.00202	0.00954	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.0018	0.00847	CcSEcCtD
Ondansetron—Injection site pain—Carmustine—melanoma	0.00178	0.0084	CcSEcCtD
Ondansetron—Foetor hepaticus—Docetaxel—melanoma	0.00165	0.00776	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.00152	0.00719	CcSEcCtD
Ondansetron—Injection site reaction—Carmustine—melanoma	0.00144	0.00682	CcSEcCtD
Ondansetron—Supraventricular tachycardia—Docetaxel—melanoma	0.00143	0.00672	CcSEcCtD
Ondansetron—Musculoskeletal pain—Temozolomide—melanoma	0.00142	0.00671	CcSEcCtD
Ondansetron—Redness—Docetaxel—melanoma	0.00138	0.00653	CcSEcCtD
Ondansetron—Liver disorder—Docetaxel—melanoma	0.00137	0.00646	CcSEcCtD
Ondansetron—Erythema multiforme—Vemurafenib—melanoma	0.0013	0.00616	CcSEcCtD
Ondansetron—Eye disorder—Vemurafenib—melanoma	0.00129	0.00608	CcSEcCtD
Ondansetron—Cardiac disorder—Vemurafenib—melanoma	0.00128	0.00604	CcSEcCtD
Ondansetron—Hepatic failure—Dactinomycin—melanoma	0.00125	0.00592	CcSEcCtD
Ondansetron—Angiopathy—Vemurafenib—melanoma	0.00125	0.00591	CcSEcCtD
Ondansetron—Mediastinal disorder—Vemurafenib—melanoma	0.00124	0.00587	CcSEcCtD
Ondansetron—Chills—Vemurafenib—melanoma	0.00124	0.00584	CcSEcCtD
Ondansetron—Erythema—Vemurafenib—melanoma	0.0012	0.00567	CcSEcCtD
Ondansetron—Swelling—Carmustine—melanoma	0.0012	0.00564	CcSEcCtD
Ondansetron—Myocardial ischaemia—Docetaxel—melanoma	0.00116	0.00548	CcSEcCtD
Ondansetron—Hepatic failure—Temozolomide—melanoma	0.00113	0.00535	CcSEcCtD
Ondansetron—Cough—Vemurafenib—melanoma	0.00105	0.00495	CcSEcCtD
Ondansetron—Liver function test abnormal—Dactinomycin—melanoma	0.00104	0.00491	CcSEcCtD
Ondansetron—Bronchospasm—Bleomycin—melanoma	0.00103	0.00485	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00102	0.00479	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00101	0.00479	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.00101	0.00479	CcSEcCtD
Ondansetron—Anaphylactic shock—Vemurafenib—melanoma	0.00098	0.00462	CcSEcCtD
Ondansetron—Liver function test abnormal—Carmustine—melanoma	0.000974	0.00459	CcSEcCtD
Ondansetron—Nervous system disorder—Vemurafenib—melanoma	0.000961	0.00454	CcSEcCtD
Ondansetron—Hypokalaemia—Carmustine—melanoma	0.00096	0.00453	CcSEcCtD
Ondansetron—Skin disorder—Vemurafenib—melanoma	0.000952	0.00449	CcSEcCtD
Ondansetron—Hepatocellular injury—Docetaxel—melanoma	0.000934	0.00441	CcSEcCtD
Ondansetron—Injection site reaction—Docetaxel—melanoma	0.000928	0.00438	CcSEcCtD
Ondansetron—Hypokalaemia—Temozolomide—melanoma	0.000928	0.00438	CcSEcCtD
Ondansetron—Acute coronary syndrome—Bleomycin—melanoma	0.000918	0.00433	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000918	0.00433	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000918	0.00433	CcSEcCtD
Ondansetron—Hypotension—Vemurafenib—melanoma	0.000916	0.00432	CcSEcCtD
Ondansetron—Myocardial infarction—Bleomycin—melanoma	0.000913	0.00431	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000861	0.00406	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vemurafenib—melanoma	0.000846	0.00399	CcSEcCtD
Ondansetron—Fatigue—Vemurafenib—melanoma	0.000845	0.00399	CcSEcCtD
Ondansetron—Haemoglobin—Bleomycin—melanoma	0.00084	0.00396	CcSEcCtD
Ondansetron—Constipation—Vemurafenib—melanoma	0.000838	0.00396	CcSEcCtD
Ondansetron—Haemorrhage—Bleomycin—melanoma	0.000836	0.00394	CcSEcCtD
Ondansetron—Dysuria—Temozolomide—melanoma	0.000824	0.00389	CcSEcCtD
Ondansetron—Urinary tract infection—Carmustine—melanoma	0.00079	0.00373	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000779	0.00367	CcSEcCtD
Ondansetron—Flushing—Bleomycin—melanoma	0.000776	0.00366	CcSEcCtD
Ondansetron—Body temperature increased—Vemurafenib—melanoma	0.000775	0.00366	CcSEcCtD
Ondansetron—Swelling—Docetaxel—melanoma	0.000768	0.00363	CcSEcCtD
Ondansetron—Urinary tract infection—Temozolomide—melanoma	0.000764	0.0036	CcSEcCtD
Ondansetron—Hepatic failure—Docetaxel—melanoma	0.000754	0.00356	CcSEcCtD
Ondansetron—Chills—Bleomycin—melanoma	0.00075	0.00354	CcSEcCtD
Ondansetron—Hepatobiliary disease—Temozolomide—melanoma	0.000743	0.00351	CcSEcCtD
Ondansetron—Erythema multiforme—Dactinomycin—melanoma	0.000737	0.00348	CcSEcCtD
Ondansetron—Haemoglobin—Carmustine—melanoma	0.000733	0.00346	CcSEcCtD
Ondansetron—Haemorrhage—Carmustine—melanoma	0.00073	0.00344	CcSEcCtD
Ondansetron—Erythema—Bleomycin—melanoma	0.000728	0.00343	CcSEcCtD
Ondansetron—Flushing—Dactinomycin—melanoma	0.000724	0.00341	CcSEcCtD
Ondansetron—Hypersensitivity—Vemurafenib—melanoma	0.000722	0.00341	CcSEcCtD
Ondansetron—Visual disturbance—Docetaxel—melanoma	0.000715	0.00337	CcSEcCtD
Ondansetron—Atrial fibrillation—Docetaxel—melanoma	0.000715	0.00337	CcSEcCtD
Ondansetron—Haemoglobin—Temozolomide—melanoma	0.000709	0.00334	CcSEcCtD
Ondansetron—Haemorrhage—Temozolomide—melanoma	0.000705	0.00333	CcSEcCtD
Ondansetron—Asthenia—Vemurafenib—melanoma	0.000703	0.00332	CcSEcCtD
Ondansetron—Visual impairment—Carmustine—melanoma	0.000703	0.00332	CcSEcCtD
Ondansetron—Chills—Dactinomycin—melanoma	0.0007	0.0033	CcSEcCtD
Ondansetron—Pruritus—Vemurafenib—melanoma	0.000694	0.00327	CcSEcCtD
Ondansetron—Eye disorder—Carmustine—melanoma	0.000682	0.00322	CcSEcCtD
Ondansetron—Visual impairment—Temozolomide—melanoma	0.00068	0.00321	CcSEcCtD
Ondansetron—Erythema—Dactinomycin—melanoma	0.000679	0.0032	CcSEcCtD
Ondansetron—Flushing—Carmustine—melanoma	0.000677	0.0032	CcSEcCtD
Ondansetron—Ill-defined disorder—Bleomycin—melanoma	0.000675	0.00319	CcSEcCtD
Ondansetron—Diarrhoea—Vemurafenib—melanoma	0.000671	0.00316	CcSEcCtD
Ondansetron—Erythema multiforme—Temozolomide—melanoma	0.000667	0.00315	CcSEcCtD
Ondansetron—Eye disorder—Temozolomide—melanoma	0.000659	0.00311	CcSEcCtD
Ondansetron—Malaise—Bleomycin—melanoma	0.000656	0.0031	CcSEcCtD
Ondansetron—Cardiac disorder—Temozolomide—melanoma	0.000654	0.00309	CcSEcCtD
Ondansetron—Flushing—Temozolomide—melanoma	0.000654	0.00309	CcSEcCtD
Ondansetron—Arrhythmia—Carmustine—melanoma	0.000652	0.00308	CcSEcCtD
Ondansetron—Dizziness—Vemurafenib—melanoma	0.000648	0.00306	CcSEcCtD
Ondansetron—Angiopathy—Temozolomide—melanoma	0.00064	0.00302	CcSEcCtD
Ondansetron—Immune system disorder—Temozolomide—melanoma	0.000637	0.00301	CcSEcCtD
Ondansetron—Mediastinal disorder—Temozolomide—melanoma	0.000636	0.003	CcSEcCtD
Ondansetron—Erythema—Carmustine—melanoma	0.000635	0.003	CcSEcCtD
Ondansetron—Cough—Bleomycin—melanoma	0.000635	0.003	CcSEcCtD
Ondansetron—Chills—Temozolomide—melanoma	0.000633	0.00299	CcSEcCtD
Ondansetron—Ill-defined disorder—Dactinomycin—melanoma	0.00063	0.00297	CcSEcCtD
Ondansetron—Liver function test abnormal—Docetaxel—melanoma	0.000626	0.00295	CcSEcCtD
Ondansetron—Vomiting—Vemurafenib—melanoma	0.000623	0.00294	CcSEcCtD
Ondansetron—Chest pain—Bleomycin—melanoma	0.00062	0.00292	CcSEcCtD
Ondansetron—Rash—Vemurafenib—melanoma	0.000618	0.00292	CcSEcCtD
Ondansetron—Dermatitis—Vemurafenib—melanoma	0.000617	0.00291	CcSEcCtD
Ondansetron—Headache—Vemurafenib—melanoma	0.000614	0.0029	CcSEcCtD
Ondansetron—Erythema—Temozolomide—melanoma	0.000614	0.0029	CcSEcCtD
Ondansetron—Discomfort—Bleomycin—melanoma	0.000612	0.00289	CcSEcCtD
Ondansetron—Malaise—Dactinomycin—melanoma	0.000612	0.00289	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Docetaxel—melanoma	0.00061	0.00288	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00061	0.00288	CcSEcCtD
Ondansetron—Vision blurred—Carmustine—melanoma	0.000599	0.00282	CcSEcCtD
Ondansetron—Tremor—Carmustine—melanoma	0.000595	0.00281	CcSEcCtD
Ondansetron—Anaphylactic shock—Bleomycin—melanoma	0.000594	0.0028	CcSEcCtD
Ondansetron—Agitation—Carmustine—melanoma	0.000584	0.00275	CcSEcCtD
Ondansetron—Vision blurred—Temozolomide—melanoma	0.000579	0.00273	CcSEcCtD
Ondansetron—Bronchospasm—Docetaxel—melanoma	0.000576	0.00272	CcSEcCtD
Ondansetron—Tremor—Temozolomide—melanoma	0.000575	0.00271	CcSEcCtD
Ondansetron—Discomfort—Dactinomycin—melanoma	0.000571	0.00269	CcSEcCtD
Ondansetron—Angina pectoris—Docetaxel—melanoma	0.000571	0.00269	CcSEcCtD
Ondansetron—Ill-defined disorder—Temozolomide—melanoma	0.00057	0.00269	CcSEcCtD
Ondansetron—Agitation—Temozolomide—melanoma	0.000564	0.00266	CcSEcCtD
Ondansetron—Angioedema—Temozolomide—melanoma	0.000561	0.00265	CcSEcCtD
Ondansetron—Hypotension—Bleomycin—melanoma	0.000555	0.00262	CcSEcCtD
Ondansetron—Malaise—Temozolomide—melanoma	0.000554	0.00261	CcSEcCtD
Ondansetron—Convulsion—Carmustine—melanoma	0.00055	0.0026	CcSEcCtD
Ondansetron—Palpitations—Temozolomide—melanoma	0.000542	0.00256	CcSEcCtD
Ondansetron—Chest pain—Carmustine—melanoma	0.000541	0.00255	CcSEcCtD
Ondansetron—Anxiety—Carmustine—melanoma	0.000539	0.00254	CcSEcCtD
Ondansetron—Cough—Temozolomide—melanoma	0.000536	0.00253	CcSEcCtD
Ondansetron—Paraesthesia—Bleomycin—melanoma	0.000533	0.00252	CcSEcCtD
Ondansetron—Convulsion—Temozolomide—melanoma	0.000532	0.00251	CcSEcCtD
Ondansetron—Dyspnoea—Bleomycin—melanoma	0.000529	0.0025	CcSEcCtD
Ondansetron—Anxiety—Temozolomide—melanoma	0.000521	0.00246	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000519	0.00245	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000518	0.00244	CcSEcCtD
Ondansetron—Discomfort—Temozolomide—melanoma	0.000516	0.00244	CcSEcCtD
Ondansetron—Acute coronary syndrome—Docetaxel—melanoma	0.000515	0.00243	CcSEcCtD
Ondansetron—Myocardial infarction—Docetaxel—melanoma	0.000512	0.00242	CcSEcCtD
Ondansetron—Dry mouth—Temozolomide—melanoma	0.000511	0.00241	CcSEcCtD
Ondansetron—Pain—Bleomycin—melanoma	0.000508	0.0024	CcSEcCtD
Ondansetron—Tachycardia—Carmustine—melanoma	0.000506	0.00239	CcSEcCtD
Ondansetron—Anaphylactic shock—Temozolomide—melanoma	0.000501	0.00236	CcSEcCtD
Ondansetron—Hepatobiliary disease—Docetaxel—melanoma	0.000494	0.00233	CcSEcCtD
Ondansetron—Nervous system disorder—Temozolomide—melanoma	0.000491	0.00232	CcSEcCtD
Ondansetron—Feeling abnormal—Bleomycin—melanoma	0.000489	0.00231	CcSEcCtD
Ondansetron—Skin disorder—Temozolomide—melanoma	0.000487	0.0023	CcSEcCtD
Ondansetron—Hypotension—Carmustine—melanoma	0.000484	0.00229	CcSEcCtD
Ondansetron—Fatigue—Dactinomycin—melanoma	0.000478	0.00225	CcSEcCtD
Ondansetron—Pain—Dactinomycin—melanoma	0.000474	0.00223	CcSEcCtD
Ondansetron—Urticaria—Bleomycin—melanoma	0.000472	0.00223	CcSEcCtD
Ondansetron—Haemoglobin—Docetaxel—melanoma	0.000471	0.00222	CcSEcCtD
Ondansetron—Body temperature increased—Bleomycin—melanoma	0.000469	0.00222	CcSEcCtD
Ondansetron—Haemorrhage—Docetaxel—melanoma	0.000469	0.00221	CcSEcCtD
Ondansetron—Paraesthesia—Carmustine—melanoma	0.000466	0.0022	CcSEcCtD
Ondansetron—Dyspnoea—Carmustine—melanoma	0.000462	0.00218	CcSEcCtD
Ondansetron—Somnolence—Carmustine—melanoma	0.000461	0.00217	CcSEcCtD
Ondansetron—Feeling abnormal—Dactinomycin—melanoma	0.000456	0.00215	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dactinomycin—melanoma	0.000453	0.00214	CcSEcCtD
Ondansetron—Visual impairment—Docetaxel—melanoma	0.000452	0.00213	CcSEcCtD
Ondansetron—Paraesthesia—Temozolomide—melanoma	0.00045	0.00212	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Carmustine—melanoma	0.000448	0.00211	CcSEcCtD
Ondansetron—Dyspnoea—Temozolomide—melanoma	0.000447	0.00211	CcSEcCtD
Ondansetron—Somnolence—Temozolomide—melanoma	0.000445	0.0021	CcSEcCtD
Ondansetron—Erythema multiforme—Docetaxel—melanoma	0.000443	0.00209	CcSEcCtD
Ondansetron—Constipation—Carmustine—melanoma	0.000443	0.00209	CcSEcCtD
Ondansetron—Pain—Carmustine—melanoma	0.000443	0.00209	CcSEcCtD
Ondansetron—Eye disorder—Docetaxel—melanoma	0.000438	0.00207	CcSEcCtD
Ondansetron—Abdominal pain—Dactinomycin—melanoma	0.000438	0.00207	CcSEcCtD
Ondansetron—Body temperature increased—Dactinomycin—melanoma	0.000438	0.00207	CcSEcCtD
Ondansetron—Hypersensitivity—Bleomycin—melanoma	0.000438	0.00206	CcSEcCtD
Ondansetron—Flushing—Docetaxel—melanoma	0.000435	0.00205	CcSEcCtD
Ondansetron—Cardiac disorder—Docetaxel—melanoma	0.000435	0.00205	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Temozolomide—melanoma	0.000433	0.00204	CcSEcCtD
Ondansetron—Fatigue—Temozolomide—melanoma	0.000432	0.00204	CcSEcCtD
Ondansetron—Pain—Temozolomide—melanoma	0.000428	0.00202	CcSEcCtD
Ondansetron—Constipation—Temozolomide—melanoma	0.000428	0.00202	CcSEcCtD
Ondansetron—Feeling abnormal—Carmustine—melanoma	0.000427	0.00202	CcSEcCtD
Ondansetron—Asthenia—Bleomycin—melanoma	0.000426	0.00201	CcSEcCtD
Ondansetron—Angiopathy—Docetaxel—melanoma	0.000425	0.00201	CcSEcCtD
Ondansetron—Gastrointestinal pain—Carmustine—melanoma	0.000424	0.002	CcSEcCtD
Ondansetron—Immune system disorder—Docetaxel—melanoma	0.000424	0.002	CcSEcCtD
Ondansetron—Mediastinal disorder—Docetaxel—melanoma	0.000423	0.00199	CcSEcCtD
Ondansetron—Chills—Docetaxel—melanoma	0.000421	0.00199	CcSEcCtD
Ondansetron—Pruritus—Bleomycin—melanoma	0.00042	0.00198	CcSEcCtD
Ondansetron—Arrhythmia—Docetaxel—melanoma	0.000419	0.00198	CcSEcCtD
Ondansetron—Feeling abnormal—Temozolomide—melanoma	0.000413	0.00195	CcSEcCtD
Ondansetron—Abdominal pain—Carmustine—melanoma	0.00041	0.00193	CcSEcCtD
Ondansetron—Body temperature increased—Carmustine—melanoma	0.00041	0.00193	CcSEcCtD
Ondansetron—Gastrointestinal pain—Temozolomide—melanoma	0.00041	0.00193	CcSEcCtD
Ondansetron—Erythema—Docetaxel—melanoma	0.000408	0.00193	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—melanoma	0.000408	0.00193	CcSEcCtD
Ondansetron—Urticaria—Temozolomide—melanoma	0.000398	0.00188	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—melanoma	0.000397	0.00187	CcSEcCtD
Ondansetron—Abdominal pain—Temozolomide—melanoma	0.000396	0.00187	CcSEcCtD
Ondansetron—Body temperature increased—Temozolomide—melanoma	0.000396	0.00187	CcSEcCtD
Ondansetron—Hypersensitivity—Carmustine—melanoma	0.000382	0.0018	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—melanoma	0.000379	0.00179	CcSEcCtD
Ondansetron—Vomiting—Bleomycin—melanoma	0.000378	0.00178	CcSEcCtD
Ondansetron—Rash—Bleomycin—melanoma	0.000374	0.00177	CcSEcCtD
Ondansetron—Dermatitis—Bleomycin—melanoma	0.000374	0.00177	CcSEcCtD
Ondansetron—Asthenia—Carmustine—melanoma	0.000372	0.00175	CcSEcCtD
Ondansetron—Hypersensitivity—Temozolomide—melanoma	0.000369	0.00174	CcSEcCtD
Ondansetron—Syncope—Docetaxel—melanoma	0.000366	0.00173	CcSEcCtD
Ondansetron—Palpitations—Docetaxel—melanoma	0.000361	0.0017	CcSEcCtD
Ondansetron—Asthenia—Temozolomide—melanoma	0.000359	0.0017	CcSEcCtD
Ondansetron—Loss of consciousness—Docetaxel—melanoma	0.000359	0.00169	CcSEcCtD
Ondansetron—Cough—Docetaxel—melanoma	0.000356	0.00168	CcSEcCtD
Ondansetron—Diarrhoea—Carmustine—melanoma	0.000355	0.00167	CcSEcCtD
Ondansetron—Pruritus—Temozolomide—melanoma	0.000354	0.00167	CcSEcCtD
Ondansetron—Convulsion—Docetaxel—melanoma	0.000354	0.00167	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—melanoma	0.000352	0.00166	CcSEcCtD
Ondansetron—Rash—Dactinomycin—melanoma	0.000349	0.00165	CcSEcCtD
Ondansetron—Chest pain—Docetaxel—melanoma	0.000348	0.00164	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000345	0.00163	CcSEcCtD
Ondansetron—Dizziness—Carmustine—melanoma	0.000343	0.00162	CcSEcCtD
Ondansetron—Diarrhoea—Temozolomide—melanoma	0.000343	0.00162	CcSEcCtD
Ondansetron—Dry mouth—Docetaxel—melanoma	0.00034	0.0016	CcSEcCtD
Ondansetron—Anaphylactic shock—Docetaxel—melanoma	0.000333	0.00157	CcSEcCtD
Ondansetron—Dizziness—Temozolomide—melanoma	0.000331	0.00156	CcSEcCtD
Ondansetron—Vomiting—Carmustine—melanoma	0.00033	0.00156	CcSEcCtD
Ondansetron—Shock—Docetaxel—melanoma	0.000328	0.00155	CcSEcCtD
Ondansetron—Rash—Carmustine—melanoma	0.000327	0.00154	CcSEcCtD
Ondansetron—Nervous system disorder—Docetaxel—melanoma	0.000327	0.00154	CcSEcCtD
Ondansetron—Dermatitis—Carmustine—melanoma	0.000327	0.00154	CcSEcCtD
Ondansetron—Tachycardia—Docetaxel—melanoma	0.000325	0.00153	CcSEcCtD
Ondansetron—Headache—Carmustine—melanoma	0.000325	0.00153	CcSEcCtD
Ondansetron—Skin disorder—Docetaxel—melanoma	0.000324	0.00153	CcSEcCtD
Ondansetron—Vomiting—Temozolomide—melanoma	0.000319	0.0015	CcSEcCtD
Ondansetron—Rash—Temozolomide—melanoma	0.000316	0.00149	CcSEcCtD
Ondansetron—Dermatitis—Temozolomide—melanoma	0.000316	0.00149	CcSEcCtD
Ondansetron—Headache—Temozolomide—melanoma	0.000314	0.00148	CcSEcCtD
Ondansetron—Hypotension—Docetaxel—melanoma	0.000311	0.00147	CcSEcCtD
Ondansetron—Paraesthesia—Docetaxel—melanoma	0.000299	0.00141	CcSEcCtD
Ondansetron—Dyspnoea—Docetaxel—melanoma	0.000297	0.0014	CcSEcCtD
Ondansetron—Somnolence—Docetaxel—melanoma	0.000296	0.0014	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Docetaxel—melanoma	0.000288	0.00136	CcSEcCtD
Ondansetron—Fatigue—Docetaxel—melanoma	0.000287	0.00136	CcSEcCtD
Ondansetron—Pain—Docetaxel—melanoma	0.000285	0.00134	CcSEcCtD
Ondansetron—Constipation—Docetaxel—melanoma	0.000285	0.00134	CcSEcCtD
Ondansetron—Feeling abnormal—Docetaxel—melanoma	0.000275	0.0013	CcSEcCtD
Ondansetron—Gastrointestinal pain—Docetaxel—melanoma	0.000272	0.00129	CcSEcCtD
Ondansetron—Abdominal pain—Docetaxel—melanoma	0.000263	0.00124	CcSEcCtD
Ondansetron—Body temperature increased—Docetaxel—melanoma	0.000263	0.00124	CcSEcCtD
Ondansetron—Hypersensitivity—Docetaxel—melanoma	0.000245	0.00116	CcSEcCtD
Ondansetron—Asthenia—Docetaxel—melanoma	0.000239	0.00113	CcSEcCtD
Ondansetron—Pruritus—Docetaxel—melanoma	0.000236	0.00111	CcSEcCtD
Ondansetron—Diarrhoea—Docetaxel—melanoma	0.000228	0.00108	CcSEcCtD
Ondansetron—Dizziness—Docetaxel—melanoma	0.00022	0.00104	CcSEcCtD
Ondansetron—Vomiting—Docetaxel—melanoma	0.000212	0.000999	CcSEcCtD
Ondansetron—Rash—Docetaxel—melanoma	0.00021	0.000991	CcSEcCtD
Ondansetron—Dermatitis—Docetaxel—melanoma	0.00021	0.00099	CcSEcCtD
Ondansetron—Headache—Docetaxel—melanoma	0.000209	0.000985	CcSEcCtD
Ondansetron—OPRM1—Signaling Pathways—CD80—melanoma	1.11e-05	8.39e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KIT—melanoma	1.11e-05	8.37e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CG—melanoma	1.11e-05	8.37e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APC—melanoma	1.11e-05	8.37e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NRAS—melanoma	1.11e-05	8.37e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GNA11—melanoma	1.11e-05	8.36e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CD—melanoma	1.11e-05	8.34e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—melanoma	1.1e-05	8.31e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GNA11—melanoma	1.1e-05	8.29e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGF—melanoma	1.1e-05	8.27e-05	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—melanoma	1.1e-05	8.26e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HIF1A—melanoma	1.09e-05	8.2e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—FASN—melanoma	1.09e-05	8.19e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—melanoma	1.09e-05	8.16e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.08e-05	8.12e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—FASN—melanoma	1.08e-05	8.11e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC5A5—melanoma	1.07e-05	8.05e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK3—melanoma	1.07e-05	8.02e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—FGF2—melanoma	1.06e-05	7.98e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC5A5—melanoma	1.06e-05	7.98e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PRKCA—melanoma	1.06e-05	7.96e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PRKCA—melanoma	1.06e-05	7.95e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ERCC2—melanoma	1.05e-05	7.9e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ERCC2—melanoma	1.05e-05	7.88e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—BRAF—melanoma	1.05e-05	7.87e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KDR—melanoma	1.04e-05	7.84e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GNAQ—melanoma	1.03e-05	7.78e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CD44—melanoma	1.03e-05	7.78e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GNAQ—melanoma	1.02e-05	7.71e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CD44—melanoma	1.02e-05	7.71e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1—melanoma	1.02e-05	7.66e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PLA2G6—melanoma	1.02e-05	7.64e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK1—melanoma	1.01e-05	7.63e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—melanoma	1.01e-05	7.63e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CD—melanoma	1.01e-05	7.57e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FN1—melanoma	1e-05	7.55e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1e-05	7.55e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP17A1—melanoma	9.97e-06	7.5e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—melanoma	9.97e-06	7.5e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	9.94e-06	7.48e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—melanoma	9.93e-06	7.47e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MDM2—melanoma	9.93e-06	7.47e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1B1—melanoma	9.91e-06	7.46e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAP2K1—melanoma	9.85e-06	7.41e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	9.84e-06	7.4e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1B1—melanoma	9.82e-06	7.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOTCH1—melanoma	9.82e-06	7.39e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB2—melanoma	9.79e-06	7.36e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CD—melanoma	9.78e-06	7.36e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	9.71e-06	7.31e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	9.69e-06	7.29e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CB—melanoma	9.66e-06	7.27e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CD80—melanoma	9.62e-06	7.24e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KIT—melanoma	9.6e-06	7.23e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APC—melanoma	9.6e-06	7.23e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CG—melanoma	9.6e-06	7.23e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—melanoma	9.6e-06	7.23e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—melanoma	9.58e-06	7.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGF—melanoma	9.49e-06	7.14e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GNA11—melanoma	9.42e-06	7.09e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FGF2—melanoma	9.37e-06	7.05e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—melanoma	9.28e-06	6.98e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—melanoma	9.22e-06	6.94e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—FASN—melanoma	9.22e-06	6.93e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK3—melanoma	9.2e-06	6.92e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—VCAN—melanoma	9.12e-06	6.86e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC5A5—melanoma	9.07e-06	6.82e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1B—melanoma	9.07e-06	6.82e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BRAF—melanoma	9.03e-06	6.79e-05	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—melanoma	8.97e-06	6.75e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—melanoma	8.89e-06	6.68e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—melanoma	8.87e-06	6.67e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—melanoma	8.83e-06	6.64e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—melanoma	8.8e-06	6.62e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1—melanoma	8.79e-06	6.62e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CB—melanoma	8.77e-06	6.6e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MDM2—melanoma	8.76e-06	6.59e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CD44—melanoma	8.76e-06	6.59e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GNAQ—melanoma	8.76e-06	6.59e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK1—melanoma	8.75e-06	6.58e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—melanoma	8.75e-06	6.58e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—melanoma	8.69e-06	6.54e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.67e-06	6.52e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—melanoma	8.65e-06	6.51e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—melanoma	8.64e-06	6.5e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	8.57e-06	6.45e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—melanoma	8.56e-06	6.44e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CB—melanoma	8.53e-06	6.41e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAP2K1—melanoma	8.5e-06	6.39e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	8.5e-06	6.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CD—melanoma	8.44e-06	6.35e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—melanoma	8.4e-06	6.32e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1B1—melanoma	8.4e-06	6.32e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1A—melanoma	8.37e-06	6.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	8.36e-06	6.29e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—melanoma	8.35e-06	6.28e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NFKB1—melanoma	8.31e-06	6.25e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—melanoma	8.29e-06	6.24e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—melanoma	8.27e-06	6.22e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—melanoma	8.27e-06	6.22e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—melanoma	8.19e-06	6.16e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCB1—melanoma	8.16e-06	6.14e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—melanoma	8.14e-06	6.13e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—melanoma	8.14e-06	6.12e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCB1—melanoma	8.09e-06	6.09e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FGF2—melanoma	8.08e-06	6.08e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—melanoma	8e-06	6.02e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—melanoma	8e-06	6.02e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—melanoma	7.98e-06	6.01e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—melanoma	7.91e-06	5.95e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—melanoma	7.84e-06	5.9e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—melanoma	7.83e-06	5.89e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—melanoma	7.79e-06	5.86e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP17A1—melanoma	7.7e-06	5.79e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—melanoma	7.63e-06	5.74e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—melanoma	7.59e-06	5.71e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—melanoma	7.58e-06	5.7e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MDM2—melanoma	7.56e-06	5.69e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—melanoma	7.56e-06	5.69e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—melanoma	7.54e-06	5.67e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PRKCA—melanoma	7.51e-06	5.65e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—melanoma	7.47e-06	5.62e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—melanoma	7.46e-06	5.61e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ERCC2—melanoma	7.45e-06	5.6e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—melanoma	7.45e-06	5.6e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PRKCA—melanoma	7.45e-06	5.6e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—melanoma	7.41e-06	5.57e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	7.41e-06	5.57e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ERCC2—melanoma	7.38e-06	5.56e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1A—melanoma	7.38e-06	5.55e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—melanoma	7.37e-06	5.54e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CB—melanoma	7.36e-06	5.54e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NFKB1—melanoma	7.33e-06	5.52e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CD—melanoma	7.29e-06	5.48e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CD—melanoma	7.27e-06	5.47e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GNA11—melanoma	7.27e-06	5.47e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—melanoma	7.19e-06	5.41e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—melanoma	7.19e-06	5.41e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—melanoma	7.18e-06	5.4e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—melanoma	7.13e-06	5.37e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—FASN—melanoma	7.11e-06	5.35e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—melanoma	7.07e-06	5.32e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—melanoma	7.03e-06	5.29e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC5A5—melanoma	7e-06	5.26e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—melanoma	6.94e-06	5.22e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCB1—melanoma	6.91e-06	5.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—melanoma	6.91e-06	5.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—melanoma	6.83e-06	5.14e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK1—melanoma	6.79e-06	5.11e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—melanoma	6.79e-06	5.1e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—melanoma	6.77e-06	5.09e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—melanoma	6.76e-06	5.08e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GNAQ—melanoma	6.76e-06	5.08e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CD44—melanoma	6.76e-06	5.08e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—melanoma	6.72e-06	5.06e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—melanoma	6.65e-06	5.01e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—melanoma	6.59e-06	4.96e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—melanoma	6.59e-06	4.96e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—melanoma	6.57e-06	4.94e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—melanoma	6.52e-06	4.91e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1B1—melanoma	6.48e-06	4.87e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—melanoma	6.41e-06	4.82e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—melanoma	6.4e-06	4.81e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1A—melanoma	6.37e-06	4.79e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PRKCA—melanoma	6.36e-06	4.79e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—melanoma	6.36e-06	4.78e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CB—melanoma	6.35e-06	4.78e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CB—melanoma	6.34e-06	4.77e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKB1—melanoma	6.33e-06	4.76e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ERCC2—melanoma	6.31e-06	4.75e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—melanoma	6.29e-06	4.74e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—melanoma	6.29e-06	4.73e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—melanoma	6.28e-06	4.73e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—melanoma	6.2e-06	4.67e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—melanoma	6.12e-06	4.61e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.12e-06	4.6e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK1—melanoma	5.99e-06	4.51e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—melanoma	5.99e-06	4.51e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—melanoma	5.89e-06	4.43e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—melanoma	5.88e-06	4.43e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—melanoma	5.83e-06	4.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—melanoma	5.74e-06	4.32e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—melanoma	5.7e-06	4.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—melanoma	5.69e-06	4.28e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—melanoma	5.68e-06	4.27e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—melanoma	5.67e-06	4.27e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—melanoma	5.66e-06	4.26e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—melanoma	5.63e-06	4.23e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—melanoma	5.49e-06	4.13e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—melanoma	5.48e-06	4.12e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—melanoma	5.45e-06	4.1e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—melanoma	5.43e-06	4.09e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—melanoma	5.35e-06	4.02e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCB1—melanoma	5.34e-06	4.01e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—melanoma	5.28e-06	3.98e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.23e-06	3.93e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—melanoma	5.21e-06	3.92e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—melanoma	5.2e-06	3.91e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CD—melanoma	5.17e-06	3.89e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK1—melanoma	5.17e-06	3.89e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—melanoma	5.17e-06	3.89e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CD—melanoma	5.13e-06	3.86e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—melanoma	5.11e-06	3.84e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—melanoma	5.06e-06	3.81e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—melanoma	5.03e-06	3.78e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—melanoma	4.98e-06	3.75e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PRKCA—melanoma	4.91e-06	3.69e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—melanoma	4.88e-06	3.67e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ERCC2—melanoma	4.87e-06	3.66e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—melanoma	4.81e-06	3.62e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—melanoma	4.81e-06	3.62e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—melanoma	4.81e-06	3.62e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—melanoma	4.6e-06	3.46e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CB—melanoma	4.51e-06	3.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—melanoma	4.49e-06	3.37e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CB—melanoma	4.47e-06	3.36e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—melanoma	4.47e-06	3.36e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—melanoma	4.43e-06	3.33e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CD—melanoma	4.38e-06	3.3e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—melanoma	4.37e-06	3.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—melanoma	4.34e-06	3.26e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—melanoma	4.32e-06	3.25e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—melanoma	4.25e-06	3.19e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—melanoma	4.15e-06	3.12e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—melanoma	3.97e-06	2.99e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—melanoma	3.9e-06	2.93e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—melanoma	3.87e-06	2.91e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—melanoma	3.86e-06	2.91e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—melanoma	3.86e-06	2.9e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—melanoma	3.85e-06	2.89e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CB—melanoma	3.82e-06	2.87e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—melanoma	3.78e-06	2.85e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—melanoma	3.71e-06	2.79e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—melanoma	3.66e-06	2.76e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CD—melanoma	3.38e-06	2.54e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—melanoma	3.34e-06	2.51e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—melanoma	3.3e-06	2.48e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—melanoma	3.16e-06	2.38e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—melanoma	3.16e-06	2.37e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CB—melanoma	2.95e-06	2.22e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—melanoma	2.92e-06	2.2e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—melanoma	2.75e-06	2.07e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—melanoma	2.72e-06	2.05e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—melanoma	2.55e-06	1.92e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—melanoma	2.33e-06	1.75e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—melanoma	2.24e-06	1.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—melanoma	2.23e-06	1.67e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—melanoma	1.9e-06	1.43e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—melanoma	1.8e-06	1.35e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—melanoma	1.47e-06	1.1e-05	CbGpPWpGaD
